Dianthus Therapeutics, Inc. (DNTH)
(Delayed Data from NSDQ)
$29.06 USD
-0.84 (-2.81%)
Updated Nov 8, 2024 04:00 PM ET
After-Market: $28.93 -0.13 (-0.45%) 7:58 PM ET
3-Hold of 5 3
F Value A Growth D Momentum D VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$29.06 USD
-0.84 (-2.81%)
Updated Nov 8, 2024 04:00 PM ET
After-Market: $28.93 -0.13 (-0.45%) 7:58 PM ET
3-Hold of 5 3
F Value A Growth D Momentum D VGM
Zacks News
Dianthus Therapeutics, Inc. (DNTH) Reports Q3 Loss, Tops Revenue Estimates
by Zacks Equity Research
Dianthus Therapeutics, Inc. (DNTH) delivered earnings and revenue surprises of -25.42% and 102.61%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?
Gilead Sciences (GILD) Q3 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
Gilead (GILD) delivered earnings and revenue surprises of 27.85% and 7.94%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?
Strength Seen in Dianthus Therapeutics, Inc. (DNTH): Can Its 5.7% Jump Turn into More Strength?
by Zacks Equity Research
Dianthus Therapeutics, Inc. (DNTH) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could be more strength down the road.
Dianthus Therapeutics, Inc. (DNTH) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Dianthus Therapeutics, Inc. (DNTH) delivered earnings and revenue surprises of -2% and 195.71%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
Dianthus (DNTH) Gains 18% in the Past Month: Here's Why
by Zacks Equity Research
Dianthus (DNTH) shares have rallied 18% in the past month on FDA clearance to initiate a phase II study on its lead candidate, DNTH103, to treat an autoimmune indication. Top-line data is expected in 2026.
The Zacks Analyst Blog Highlights American Eagle Outfitters, Abercrombie & Fitch, Cimpress, Dianthus Therapeutics and NVIDIA Corporation
by Zacks Equity Research
American Eagle Outfitters, Abercrombie & Fitch, Cimpress, Dianthus Therapeutics and NVIDIA Corporation are part of the Zacks top Analyst Blog.
Strong Q1 a Boon for the Rest of 2024? 5 Top Growth Picks
by Tirthankar Chakraborty
Invest in growth stocks such as American Eagle Outfitters (AEO), Abercrombie & Fitch (ANF), Cimpress (CMPR), Dianthus Therapeutics (DNTH) and NVIDIA (NVDA) as the stock market is well-poised to scale upward.
5 Top-Ranked Stocks That Have More Than Doubled Year to Date
by Sweta Killa
Amid the broad-market rally, shares of Equillium (EQ), Phunware (PHUN), Super Micro Computer (SMCI), Vaxart (VXRT) and Dianthus Therapeutics (DNTH) have more than doubled this year.